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1. Introduction  
Renal cell carcinoma (RCC) is the third most common genitourinary cancer behind prostate 
and bladder cancer, accounting for 3% of all adult malignancies (Curti, 2004). It is a highly 
metastatic and heterogeneous disease with at least 16 histologic subtypes (Eble et al., 2001; 
Lopez-Beltran et al., 2006), among which clear cell (70-80%), papillary (10-15%) and  
chromophobe (5%) are the most common (Curti, 2004). Up to 25% of patients with RCC 
have distant metastases at presentation. Another 50% develop metastases or local recurrence 
during follow-up, despite treatment of the primary tumor (Thyavihally et al., 2005). The 
average survival, following metastatic RCC, is about 4 months, and only 10% of patients 
survive for one year. The global incidence of RCC per year is close to 300000, with a male to 
female ratio of 3:2 and an estimated mortality of approximately 100000 (Arai&Kanai, 2010; 
Ferlay et al., 2010). The incidence of RCC has been rising steadily, probably because of 
incidental findings from imaging techniques performed for other reasons. It can occur at any 
age, but is most frequently diagnosed in the 40-70 year old group (Eble et al., 2001; Pascual 
& Borque, 2008; Arai&Kanai, 2010).  
Well before the advent of the modern era of genetics and molecular biology, surgeons and 
pathologists were aware of the hyper-vascular nature of RCC (Corn, 2007). The subsequent 
isolation of the von Hippel-Lindau (VHL) gene in 1993 led to the important discoveries that 
aberrant VHL is the most important risk for RCC and that VHL negatively regulates the 
hypoxia inducible factor (HIF) and thus the downstream angiogenesis pathway thereby 
engendering increased vascularity. In this chapter, we will focus on the role of the VHL-HIF 
pathway in RCC, advancements in novel therapeutics targeting this pathway and future 
directions. 
2. Von Hippel-Lindau syndrome 
VHL disease, commonly known as the VHL syndrome, is named after the German 
ophthalmologist Eugene von Hippel, and the Swedish neuropathologist Arvid Lindau, who 
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in the early 1900s, described highly vascularised tumors of the retina and the central 
nervous system (Kim&Kaelin, 2004; Ohh, 2006). VHL syndrome is the result of germ line 
mutations in VHL, a tumor-suppressor gene located on chromosome 3p25 (Seizinger et al., 
1988; Kim&Kaelin, 2004; Clark, 2009; Gossage&Eisen, 2010). It affects 1 in 35,000 individuals 
and is associated with the development of tumors in multiple organs, including the brain, 
spinal cord, pancreas, adrenal gland, epididymis (in males), broad ligament (in women) and 
kidneys (Lonser et al., 2003; Kim&Kaelin, 2004; Grubb et al., 2005; Clark, 2009). Individuals 
with VHL syndrome carry one wild type VHL allele and one faulty allele. Tumors develop 
only after the spontaneous somatic loss (loss of heterzygosity [LoH]) or inactivation, or both, 
of the remaining wild type. Thus, at cellular level, VHL syndrome  can be considered as an 
autosomal recessive disease, whilst clinically, it manifests more like an autosomal dominant 
disease because the inactivation of the wild type allele is almost guaranteed (Ohh&Kaelin, 
2003; Ohh, 2006). Apart from LoH and mutations, hypermethylation of the VHL promoter 
regions can prevent the wild-type VHL gene from expressing its functional tumor 
suppressor protein pVHL (Kim&Kaelin, 2004). The VHL gene is mutated in 50-80%   
(Weiss&Lin, 2006; Arai&Kanai, 2010) and hypermethylated in 19% (Herman et al., 1994; 
Arai&Kanai, 2010) of sporadic clear cell RCC. Clear cell RCC is the leading cause of death in 
patients with VHL mutation (Maher et al., 1990; Clark, 2009; Gossage&Eisen, 2010).  
The VHL gene, which was isolated in 1993 (Latif et al., 1993), has three exons and encodes 
for two mRNA transcripts that are translated into three types of pVHL (Ohh&Kaelin, 2003; 
Ohh, 2006). The first VHL mRNA transcript that contains all three exons, is translated into a 
larger  213 amino acid protein of approximately 24-30 kDa (pVHL30), and a smaller 160 
amino acid protein of approximately 18-19 kDa (pVHL19) due to alternative translation 
initiation (Iliopoulos et al., 1998; Schoenfeld et al., 1998; Blankenship et al., 1999; 
Safran&Kaelin, 2003). In the early days, both pVHL30 and pVHL19 were considered to be 
tumor suppressors (Iliopoulos et al., 1995; Ohh, 2006). However, further studies have cast 
doubt on the tumor suppressive role of pVHL19 (Ohh, 2006). Generally, the term ‘pVHL’ is 
used to refer to both isoforms (Kim&Kaelin, 2004; Kaelin, 2007). The second VHL mRNA 
transcript lacks exon 2 due to alternative splicing. Literature on this isoform is scant, 
although RCCs that exclusively produce this shorter VHL mRNA transcript have been 
identified (Gnarra et al., 1996; Safran&Kaelin, 2003; Ohh, 2006).  
pVHL consists of ┙ and ┚ domains (Fig.1), which are essential for its tumor suppressor 
activities (Stebbins et al., 1999; Kaelin, 2002). pVHL forms complexes with  elonginB, 
elonginC, Rbx1, and Cullin 2 to form an E3 ubiquitin ligase complex (Stebbins et al., 1999; 
Ohh et al., 2000; Tanimoto et al., 2000; Kaelin, 2002; Kaelin, 2005a; Kaelin, 2005b; 
Gossage&Eisen, 2010). The ┙ domain binds to elongin C and the ┚ domain interacts with 
hydroxylated prolines of HIF (Fig.1). This complex has multiple functions, which can be 
broadly classified into HIF-independent and HIF-dependent. The HIF-independent 
functions include maintenance of primary cilia (Hergovich et al., 2003; Baldewijns et al., 
2010), assembly of extracellular fibronectin matrix (Guo et al., 2009), regulation of apoptosis 
(Guo et al., 2009), epithelial mesenchymal transition (EMT) (Koochekpour et al., 1999; Hara 
et al., 2006), and transcriptional regulation (Yuen et al., 2007; Mikhaylova et al., 2008; 
Baldewijns et al., 2010). The best studied role is its HIF-dependent function in RCC, which is 
the degradation of HIF (Ohh, 2006; Baldewijns et al., 2010; Gossage&Eisen, 2010).  
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3. Hypoxia-inducible factor 
A hypoxic tumor microenvironment is one of the characteristics of solid tumors. Cells 
undergo a variety of adaptive changes that will facilitate their survival under hypoxic 
conditions. One such change at the molecular level is the activation of the hypoxia-sensitive 
transcription factor, HIF. HIF is a heterodimer consisting of two subunits: ┙ and ┚ (Wang et 
al., 1995; Kaluz et al., 2008). The ┚ subunit, also known as aryl hydrocarbon receptor nuclear 
translocator (ARNT), is constitutively expressed and is independent of intracellular oxygen 
tension. The oxygen-sensitive ┙ subunit, which has three further subunits, HIF-1┙, HIF-2┙, 
and HIF-3┙,  is also constitutively expressed, but is rapidly degraded under normoxic 
conditions (Semenza, 1999; Huang&Bunn, 2003; Maynard et al., 2003; Maynard&Ohh, 2004; 
Kaluz et al., 2008; Baldewijns et al., 2010). At least two mechanisms that negatively regulate 
the stability of HIF- under normoxia have been recognized: oxygen-dependent prolyl 
hydroxylation and asparaginyl hydroxylation (Lando et al., 2002a; Lando et al., 2002b; Ohh, 
2006).  
HIF-1┙ and HIF-2┙ contain an N-terminal transactivation domain (NTAD), a C-terminal 
transactivation domain (CTAD) and an oxygen-dependent degradation domain (ODDD) 
[Fig.1] (Pugh et al., 1997; Sang et al., 2002; Baldewijns et al., 2010). The ODDD has a stretch 
of proline residues. HIF-3┙ lacks the transactivation domain and has many splice variants. 
Under normoxic conditions, the proline residues within the ODDD of HIF-┙ are 
hydroxylated by prolyl hydroxylases (PH) at positions 402 and 564 (Ivan et al., 2001; 
Jaakkola et al., 2001; Schofield&Ratcliffe, 2005; Koivunen et al., 2007; Kaluz et al., 2008; 
Baldewijns et al., 2010). The pVHL-E3 ubiquitin ligase complex binds to the hydroxylated 
HIF-┙ through the  domain of pVHL and enables polyubiquitination. The 
polyubiquitinated HIF- is degraded by the 26S proteasome (Maxwell et al., 1999; Ohh et al., 
2000; Tanimoto et al., 2000; Jaakkola et al., 2001; Baldewijns et al., 2010). While the prolyl 
hydroxylation enables the binding of pVHL to HIF-  and its eventual degradation, the 
asparaginyl hydroxylation prevents the transcriptional activation of HIF target genes 
(Dames et al., 2002; Freedman et al., 2002). For transcriptional activity, HIF- requires the 
recruitment of p300/CBP transcriptional coactivators (Arany et al., 1996). The CTAD has a 
conserved C-terminal asparagine. In normoxia, the factor inhibiting HIF-1 (FIH-1), an 
oxygenase,  hydroxylates asparagine at position 803, which diminishes the recruitment of 
p300/CBP to HIF- (Freedman et al., 2002) leading to the transcriptional downregulation of  
HIF responsive elements (Mahon et al., 2001; Dames et al., 2002; Lando et al., 2002a; Lando 
et al., 2002b).  
In hypoxia, the activity of prolyl hydroxylases and FIH-1 are reduced, leading to the 
inhibition of proline and asparginyl hydroxylation, respectively. In the absence of a 
functional pVHL, the binding of the pVHL-E3 ubiquitin ligase complex to HIF- and the 
subsequent polyubiquitination and degradation of HIF- are inhibited even under normoxic 
conditions. Both events lead to the stabilization and accumulation of HIF- in cells. As a 
result, HIF- is translocated to the nucleus, where it dimerizes with HIF-. The HIF-/HIF-
 heterodimer binds to hypoxia-responsive elements (HRE) of the DNA,  recruits p300/CBP 
to the CTAD and transactivates over 60 hypoxia-inducible genes of which, vascular 
endothelial growth factor (VEGF) (angiogenesis), transforming growth factor alpha (TGF-) 
and epidermal growth factor receptor (EGFR) (proliferation), carbonic anhydrase IX (CAIX) 
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(pH regulation),  erythropoietin (EPO) (erythropoiesis), e-cadherin (EMT) and glucose 
transporter-1 (GLUT-1) (glucose metabolism) have attracted much attention (Ohh, 2006; 
Clark, 2009; Baldewijns et al., 2010). Because of the defective VHL-HIF-VEGF pathway, RCC 
is considered to be one of the most hypervascularized tumors. Hence, it is not surprising 
that considerable research in the past decade has focused on the angiogenic pathway, which 
led to the development of some promising novel therapeutics.  
 
Fig. 1. The von Hippel-Lindau-Hypoxia Inducible Factor (VHL-HIF) pathway. The details 
are given in text. In brief, under active VHL and normoxic conditions, HIF is degraded. 
When the VHL gene is inactive due to mutations or hypermethylation, HIF is stabilized, 
translocated to the nucleus and activates the transcription of over 60 hypoxia-responsive 
molecules that are involved in oncogenesis and tumor progression. Only selected molecules 
and their alleged roles in tumor progression that are discussed in this chapter are shown. X, 
represents inhibition or inactivation. N, asparagine; P, proline; PH, prolyl hydroxylases; Ub, 
ubiquitination. 
www.intechopen.com
 
The VHL-HIF Signaling in Renal Cell Carcinoma: Promises and Pitfalls 
 
61 
4. VHL inactivation and HIF-induced hypoxia responsive genes  
4.1 Vascular endothelial growth factor – mammalian target of rapamycin  
Of the many HIF-regulated angiogenic molecules, VEGF is perhaps the most studied - not 
only in RCC but also cancers in general. In humans, the VEGF system consists of five 
secreted ligands, namely VEGF-A, VEGF-B, VEGF-C, VEGF-D and placenta growth factor-1 
(PlGF) and three receptor tyrosine kinases, VEGF-R1 (flt-1), VEGF-R2 (flk1 in the mouse, 
KDR in the human), and VEGF-R3 (flt4) (Carmeliet, 2005; Hicklin&Ellis, 2005; Tammela et 
al., 2005; Cebe-Suarez et al., 2006; Donovan&Kummar, 2006; Roy et al., 2006; 
Thurston&Kitajewski, 2008; Clark, 2009; Stuttfeld&Ballmer-Hofer, 2009; Bates, 2010). VEGF-
R1 and VEGF-R2 are predominantly expressed in vascular endothelial cells and VEGF-R3 in 
lymphatic endothelial cells (Tammela et al., 2005; Thurston&Kitajewski, 2008). Hence, 
VEGF-R1 and VEGF-R2 are thought to be more important for angiogenesis and VEGF-R3 for 
lymphangiogenesis (Donovan&Kummar, 2006; Clark, 2009). The binding of the ligands to 
the receptors is an essential step in the initiation of the VEGF signaling. Generally, VEGF-R1 
binds to VEGF-A, VEGF-B and PlGF; VEGF-R2 binds to VEGF-A, VEGF-C and VEGF-D and 
VEGF-R3 to VEGF-C and VEGF-D (Cebe-Suarez et al., 2006; Stuttfeld&Ballmer-Hofer, 2009). 
The receptor-ligand binding promotes conformational changes, followed by 
phosphorylation of specific tyrosine residues of the receptor (Cebe-Suarez et al., 2006; 
Stuttfeld&Ballmer-Hofer, 2009). Subsequently, a variety of downstream signaling pathways 
is activated, of which the most studied are the RAF-MEK-ERK series of kinases and the 
phosphatidylinositol-3 kinase-protein kinase B-mammalian target of rapamycin (PI3K-AKT-
mTOR) pathway (Clark, 2009; Banumathy&Cairns, 2010). Increased mTOR, which itself is 
the result of HIF activation secondary to VHL loss, can in turn lead to an increase in HIF 
thereby maintaining a positive feedback loop that exacerbates the deleterious effects of  
VHL inactivation  (Cho et al., 2007; Clark, 2009; Banumathy&Cairns, 2010). Both pathways 
predominantly up-regulate a variety of pro-angiogenic factors, thereby imparting a hyper-
angiogenic phenotype to RCC. 
There is considerable evidence demonstrating that VEGF is significantly elevated in RCC, 
with some studies reporting its up-regulation in up to 96% of RCC (Takahashi et al., 1994). 
There is a direct correlation between VEGF expression, tumor microvascular density, 
disease progression and metastasis of RCC (Takahashi et al., 1994; Zhang et al., 2002; Fukata 
et al., 2005; Baldewijns et al., 2007; Rioux-Leclercq et al., 2007; Patard et al., 2009). Apart from 
VEGF, RCC is reported to over-express several potent pro-angiogenic factors, including 
basic fibroblast growth factor (bFGF) (Cenni et al., 2007), PlGF (Takahashi et al., 1994), 
platelet-derived growth factor (PDGF) (Xu et al., 2005a), epidermal growth factor (EGF) 
(Kedar et al., 2002), the interleukins IL-6 (Angelo et al., 2002) and IL-8 (Konig et al., 1999), 
leptin (Horiguchi et al., 2006b; Horiguchi et al., 2006a) and various chemokines (Slaton et al., 
2001; Fukata et al., 2005).  
Hence, it is not surprising that the past decade has placed much emphasis on HIF-regulated 
downstream pathways, especially angiogenesis. This has resulted in the development of 
many clinically available novel chemotherapeutic agents. They can be broadly categorized 
as VEGF inhibitors, multiple tyrosine kinase inhibitors and mTOR inhibitors. The most 
successful VEGF inhibitor is the humanized VEGF-neutralizing antibody, bevacizumab. 
Bevacizumab is thought to exert its anti-angiogenic activity by acting against the angiogenic 
endothelial cells surrounding the tumor rather than the tumor per se thus blocking the 
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supply of oxygen and nutrients to the tumors (Ellis&Hicklin, 2008; Ainsworth et al., 2009; 
Banumathy&Cairns, 2010). The clinically available multiple tyrosine kinase inhibitors are 
sunitinib, sorafenib, pazopanib and axitinib. As summarized in Table 1, they target multiple 
tyrosine kinase receptors neutralizing the downstream signaling pathways activated by 
ligand-receptor binding, as discussed above. Two of the most successful mTOR inhibitors 
are temsirolimus and everolimus. Both are rapamycin analogues and bind to FK506-binding 
protein 12 (FKBP12), which in turn binds to mTOR leading to the inhibition of the 
PI3K/Akt/mTOR pathway (Thomas et al., 2006; Abraham&Gibbons, 2007; Ainsworth et al., 
2009; Banumathy&Cairns, 2010). In addition, temsirolimus has been shown to have a direct 
inhibitory effect on HIF-┙ and VEGF (Del Bufalo et al., 2006; Motzer et al., 2008; 
Banumathy&Cairns, 2010; Houghton, 2010). 
 
Drug Target receptors Reference 
Sunitinib VEGFR1, VEGFR2,  
VEGFR3, PDGFR-┙,  
PDGFR-┚, FLT3, c-KIT, RET 
 
(Mendel et al., 2003; Faivre et 
al., 2006; Ainsworth et al., 
2009; Banumathy&Cairns, 
2010) 
Sorafenib VEGFR-2, PDGFR-┚, c-KIT,  
Raf-1 
 
(Wilhelm&Chien, 2002; 
Wilhelm et al., 2004; 
Ainsworth et al., 2009) 
Pazopanib VEGFR1, VEGFR2, VEGFR3,  
PDGFR-┙, PDGFR-┚, c-KIT 
 
(Kumar et al., 2007; 
Ainsworth et al., 2009; 
Banumathy&Cairns, 2010; 
Sternberg et al., 2010) 
Axitinib VEGFR1, VEGFR2, VEGFR3,  
PDGFR-┚, c-KIT,  
(Rugo et al., 2005; Rixe et al., 
2007) 
Table 1. Clinically available multiple tyrosine kinase inhibitors for metastatic RCC (Bullock 
et al., 2010) 
4.2 Transforming growth factor- and epidermal growth factor receptor 
TGF-  is an autocrine mitogen for fibroblasts and epithelial cells. It has structural and 
functional homology to EGF (Derynck, 1986; Everitt et al., 1997). TGF- is thought to 
mediate its biological effects through the binding of EGFR, which is a family of four closely 
related cell membrane receptors, EGFR (HER1; ErbB1), HER2 (ErbB2), HER3 (ErbB3), and 
HER4 (ErbB4) (Higashiyama et al., 2008; Pu et al., 2009). These receptors are transmembrane 
glycoproteins with an extracellular ligand-binding domain and an intracellular tyrosine 
kinase domain (Higashiyama et al., 2008; Pu et al., 2009). Ligand-binding to the extracellular 
domain of EGFR activates tyrosine kinase, resulting in autophosphorylation of EGFR and 
subsequent signal transduction leading to cell cycle progression, inhibition of apoptosis, 
induction of angiogenesis, promotion of invasion and metastasis, and other oncogenic 
activities (Derynck, 1986; Everitt et al., 1997; Gunaratnam et al., 2003; Black&Dinney, 2008; 
Lee et al., 2008; Uberall et al., 2008; Pu et al., 2009). TGF-/EGFR activation in RCC is either 
independent of, or dependent on the VHL status. While the mechanisms behind VHL-
independent activation have not been fully elucidated, the VHL-dependent TGF-/EGFR 
follows the classical pattern of HIF-1 up-regulation secondary to loss of VHL function (de 
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Paulsen et al., 2001; Gunaratnam et al., 2003; Lee et al., 2008). It has been suggested that 
TGF-┙ overproduction secondary to VHL deficiency is the consequence of  HIF activation 
and that such activation establishes an autocrine TGF-/EGFR stimulatory system leading 
to the oncogenic transformation of normal renal epithelial cells and the formation of RCC 
(Ishikawa et al., 1990; Atlas et al., 1992; Yoshida et al., 1994; Everitt et al., 1997; de Paulsen et 
al., 2001; Gunaratnam et al., 2003; Pelletier et al., 2009; Pu et al., 2009). For example, 
transgenic expression of TGF-┙ in mice leads to the formation of multiple renal cysts 
reminiscent of pre-neoplastic lesions of the human kidney, whilst the re-introduction of wild 
type VHL inhibits TGF- expression and cyst formation (Lowden et al., 1994; Everitt et al., 
1997; Knebelmann et al., 1998; de Paulsen et al., 2001; Kaelin, 2002; Gunaratnam et al., 2003). 
Many studies have reported the over expression of TGF- and EGFR in RCC (Freeman et al., 
1989; Gomella et al., 1989; Mydlo et al., 1989; Sargent et al., 1989; Petrides et al., 1990; Lager 
et al., 1994; Yoshida et al., 1994; Uhlman et al., 1995; Everitt et al., 1997; Yoshida et al., 1997; 
Ramp et al., 2000; Merseburger et al., 2005; Lee et al., 2008; Pelletier et al., 2009; Pu et al., 
2009). The expression pattern of TGF- in RCC is such that it has been identified as an ideal 
candidate for immunotherapy (Pelletier et al., 2009). The prognostic association between 
over-expression of EGFR in RCC, and development of the cancer is controversial. Two 
distinct patterns of EGFR expression have been observed: a) cytoplasmic in normal renal 
cells, and b) membranous in RCC. These observations suggest that it is not just the over 
expression of EGFR, but the location of its over-expression that determines prognosis. 
Accordingly, RCC patients with positive membranous EGFR expression may have a poorer 
survival outcome when compared with those with negative expression of membranous 
EGFR (Pu et al., 2009). However, a previous study casts doubt on this hypothesis (Kallio et 
al., 2003).  
Some studies have explored the therapeutic efficiency of EGFR inhibitors, either as single 
agents or in combination, with a success rate of around 10% (Motzer et al., 2003; Dawson et 
al., 2004; Rowinsky et al., 2004; Jermann et al., 2006; Ravaud et al., 2008; Gordon et al., 2009; 
Pu et al., 2009). Interestingly however, results of anti-EGFR therapy in other cancers show a 
lack of correlation between EGFR expression and response to therapy, suggesting that 
differential intracellular signaling events rather than the mere expression of EGFR  may also 
play significant roles in predicting response to anti-EGFR therapy (Marks et al., 2008; 
Gordon et al., 2009). Furthermore, RCC cells with wild type VHL have been shown to be 
more sensitive to anti-EGFR treatment than those with mutated VHL (Perera et al., 2000; 
Gordon et al., 2009).  
4.3 Erythropoietin 
Paraneoplastic erythrocytosis is a salient feature of many cancers, including RCC in which 
about 5% of patients are polycythemic (Wiesener et al., 2002; Wiesener et al., 2007; Papworth 
et al., 2009). In adults, the kidney is the major source of EPO. EPO regulates erythropoiesis 
and is the only hematopoietic cytokine whose production is regulated by hypoxia 
(Lacombe&Mayeux, 1999; Fandrey, 2004; Michael et al., 2007; Wiesener et al., 2007). 
Although RCC is thought to arise from proximal tubular epithelial cells (PTEC), normal 
PTEC do not express detectable levels of EPO even under hypoxic conditions (Wiesener et 
al., 2002; Wiesener et al., 2007). This pointed towards the role of molecular mechanisms that 
transform a non-EPO expressing PTEC to an EPO-expressing RCC , leading to the 
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identification of the link between VHL mutation  and the subsequent HIF-mediated EPO 
upregulation in RCC  (Da Silva et al., 1990; Noguchi et al., 1999; Wiesener et al., 2002; 
Pastore et al., 2003; Lee et al., 2005; Wiesener et al., 2007; Rad et al., 2008; Papworth et al., 
2009). Enhanced expression of EPO and its receptor EPOR has been reported in cultured 
RCC cells and in patient samples, the reported prevalence ranges from 33 - 84% (Murphy et 
al., 1970; Hagiwara et al., 1984; Da Silva et al., 1990; Ljungberg et al., 1992; Noguchi et al., 
1999; Wiesener et al., 2002; Sakamoto et al., 2003; Lee et al., 2005; Michael et al., 2007; 
Wiesener et al., 2007; Papworth et al., 2009). 
Although 33-84% of the RCC patients have elevated plasma level of EPO, only 5% of them 
are polycythemic  (Kazal&Erslev, 1975; Ljungberg et al., 1992; Michael et al., 2007; Wiesener 
et al., 2007; Papworth et al., 2009). The lack of correlation between paraneoplastic EPO 
production and paraneoplastic erythrocytosis has led to the suggestion that other cancer-
related factors can counterbalance the effect of increased EPO. One of the well studied 
factors is the reduced iron availability and the resultant anemia in cancer patients. Since 
recombinant human EPO (rhEPO) is frequently used to treat anemia in patients with cancer, 
the presence of EPOR in RCC has raised concern (Lai&Grandis, 2006; Papworth et al., 2009). 
As EPOR is over-expressed in RCC, and EPO exerts its effects through its binding of EPOR, 
exogenous rhEPO could enhance tumor aggressiveness as reported in breast and head and 
neck cancers (Henke et al., 2003; Leyland-Jones et al., 2005; Wiesener et al., 2007). 
Furthermore, EPO has been shown to reduce cisplatin-induced apoptosis in cultured RCC 
cells (Li et al., 2007). In contrast, EPO sensitized RCC cell lines to vinblastin and 
daunorubicin-induced apoptosis (Carvalho et al., 2005). 
4.4 E-cadherin 
Cell-cell adherence, mediated by intercellular junctional complexes, plays an important role 
in tissue formation and maintenance of cell phenotypes. Intercellular junctional complexes 
are composed of tight junctions, adherence junctions and desmosomes (Cavallaro & 
Christofori, 2004; Krishnamachary et al., 2006; Migita et al., 2008). E-cadherin, a 
transmembrane glycoprotein, is the principal component of adherence junctions and 
desmosomes in epithelial cells (Cavallaro&Christofori, 2004; Krishnamachary et al., 2006). 
The extracellular domain of E-cadherin mediates cell-cell adherence through homophilic 
interaction with the E-cadherin of adjacent cells, whereas the intracellular domain binds 
with the cytoskeleton via a protein complex containing ┙-, ß- and ┛ -catenins (Behrens et al., 
1989; Cavallaro&Christofori, 2004; Krishnamachary et al., 2006; Russell&Ohh, 2007). EMT is 
the hallmark of many cancers, in which E-cadherin-mediated cell-cell adherence is lost and 
the cells attain hyper-proliferative, invasive and metastatic properties (Behrens et al., 1989; 
Thiery, 2002; Krishnamachary et al., 2006). While the reasons for loss of E-cadherin in 
cancers are undoubtedly multifactoral, many studies have shown a direct role of VHL in 
regulating E-cadherin expression in RCC (Esteban et al., 2006; Krishnamachary et al., 2006; 
Evans et al., 2007; Russell&Ohh, 2007).  
The loss of VHL in turn leads to a loss or significant downregulation of E-cadherin and its 
re-introduction restores E-cadherin expression in RCC (Esteban et al., 2006; Krishnamachary 
et al., 2006; Russell&Ohh, 2007). Further reports of E-cadherin loss in pre-malignant foci of 
VHL patients has led to the suggestion that E-cadherin loss is an early step in the 
pathogenesis of RCC, attributed to VHL inactivation (Esteban et al., 2006; Russell&Ohh, 
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2007). In line with these observations, tissue microarray of human RCC samples has shown 
the lack of E-cadherin immunoreactivity in VHL-deficient samples (Gervais et al., 2007). 
This study also found that low Fuhrman grade samples were positive for E-cadherin and 
VHL immunostaining and had a better prognosis. Conversely, high-grade tumors were 
negative for E-cadherin and VHL immunoreactivity and had a worse prognosis. However, 
these observations have been contradicted by another report, which found no association 
between E-cadherin expression, tumor grade and prognosis in RCC (Ronkainen et al., 2010). 
4.5 Glucose transporter-1 
Glucose is the major substrate for energy production in mammalian cells. The intracellular 
transport of glucose and its oxidative metabolism are vital for normal functioning of cells. 
Intracellular glucose transport is facilitated by a family of 14 glucose transporters (GLUT), of 
which GLUT-1 is the most studied (Macheda et al., 2005; Ozcan et al., 2007; Suganuma et al., 
2007; Lidgren et al., 2008). Due to rapid proliferative rate relative to vascular support of 
cancer cells, the tumor microenvironment is in a constant state of hypoxia (Ozcan et al., 
2007). In order to counteract the deleterious effects of hypoxia, such as apoptosis and 
necrosis, malignant cells undergo adaptive and genetic changes. One such change is 
increased uptake of glucose when compared with normal cells through accelerated 
glycolysis – often referred to as ‘glycolytic switch’ or ‘Warburg effect’ (Warburg, 1956; 
Airley&Mobasheri, 2007; Singer et al., 2011). This is largely mediated by the up-regulation of 
GLUT especially GLUT-1 (Binder et al., 1997; Smith, 1999; Medina&Owen, 2002; 
Airley&Mobasheri, 2007; Ozcan et al., 2007; Suganuma et al., 2007). It is now well 
established that accelerated glycolysis and increased glucose uptake mediated by GLUT-1 
are the hallmarks of many malignant tumors and that these adaptive changes in glucose 
metabolism favor survival, proliferation and metastasis of tumor cells, even under hypoxic 
conditions (Airley&Mobasheri, 2007; Ozcan et al., 2007; Singer et al., 2011).  
The link between VHL-HIF and GLUT-1 has been well established. GLUT-1 is over-
expressed in VHL-mutated mice and the GLUT-1 promoter region has an HRE (Ebert et al., 
1995; Park et al., 2007; Lidgren et al., 2008). While the basal level of expression of GLUT-1 in 
normal PTEC is a subject of debate (Nagase et al., 1995; Ozcan et al., 2007), the over-
expression of GLUT-1 in RCC has been demonstrated by many studies (Nagase et al., 1995; 
Miyakita et al., 2002; Ozcan et al., 2007; Suganuma et al., 2007; Lidgren et al., 2008; Singer et 
al., 2011). All of these studies concluded that GLUT-1 is over-expressed markedly in clear 
cell RCC compared with other RCC subtypes, confirming the link between VHL aberration 
and the subsequent HIF up-regulation. Lactate is one of the byproducts of glycolysis. Due to 
the enhanced glycolysis, RCC patients are reported to have increased glycolytic enzymes 
and higher levels of lactate in their serum (Gao et al., 2008). Increased dependence of cancer 
cells on glycolysis suggests that glycolysis inhibition may be a therapeutic option. Although 
not well-documented in RCC, experimental glycolysis inhibition has produced anti-cancer 
effects in certain cancer cell lines  (Xu et al., 2005b; Pelicano et al., 2006). 
4.6 Carbonic anhydrase IX 
CAIX is a membrane-bound glycoprotein belonging to the carbonic anhydrase (CA) family 
of enzymes and is thought to promote cell proliferation, oncogenesis and tumor progression 
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in response to hypoxia (Grabmaier et al., 2000; Ivanov et al., 2001; Bui et al., 2003; 
Lawrentschuk et al., 2011). There are at least 15 isoforms of CA. These enzymes play an 
important role in the regulation of pH of cells by catalyzing one of the vital reactions of 
biological systems  - the reversible hydration of  CO2  into bicarbonate and hydrogen ions, 
CO2+H2O  HCO3- + H+  (Opavsky et al., 1996; Pastorekova et al., 2008; Stillebroer et al., 
2010). As discussed above, enhanced glycolysis is a hallmark of cancer cells, which results in 
accumulation of lactate and a hypoxic acidic microenvironment. CO2 is a significant source 
of hypoxia and acidity in tumors (Pastorekova et al., 2008). Enhanced CAIX expression and 
the resultant rapid reversible conversion of CO2 to H+ helps to maintain an acidic, hypoxic 
microenvironment thereby sustaining tumor progression (Opavsky et al., 1996; Dorai et al., 
2006; Pastorekova et al., 2008; Patard et al., 2008; Stillebroer et al., 2010). CAIX is regulated 
by HIF and the correlation between VHL-HIF-CAIX is well-established (Wykoff et al., 2000; 
Grabmaier et al., 2004; Patard et al., 2008; Kaluz et al., 2009; Lawrentschuk et al., 2011). 
Enhanced expression of CAIX has been well documented in RCC (Bui et al., 2003; Zavada et 
al., 2003; Atkins et al., 2005; Al-Ahmadie et al., 2008; Jensen et al., 2008; Li et al., 2008; Patard 
et al., 2008; Patard et al., 2009; Stillebroer et al., 2010; Zhou et al., 2010). However, in contrast 
to other cancers, enhanced CAIX in RCC is associated with a better prognosis. Furthermore, 
metastatic patients with higher tumoral CAIX expression showed a better response to 
interleukin-2 treatment (Atkins et al., 2005). Based on the VHL-CAIX status of RCC, Patard 
and colleagues (Patard et al., 2008) stratified RCC patients into three distinct groups: 
patients with both VHL mutation and high CAIX expression had the most favourable 
prognosis; patients with either VHL mutation or high CAIX expression had an intermediate 
prognosis; and patients with neither VHL mutation nor high CAIX expression had the worst 
prognosis.  
5. Promises, pitfalls and future directions 
The past decade has witnessed an unprecedented increase in the understanding of 
molecular mechanisms of RCC, of which, the VHL-HIF pathway arguably is the most 
explored. Not surprisingly, this has resulted in promising, clinically available novel 
therapeutic agents. Patients were reported to have progression-free survival with these 
novel therapeutic agents, and many new drugs are under clinical trial, offering hope for 
better treatment strategies in the future. However, progression-free survival, which occurs 
in approximately 10% of selected patients, is generally measured in months, rather than 
years. Moreover, there is currently no compound, either singly or in combination, which is 
capable of producing a complete response in metastatic RCC. Systemic toxicity and 
resistance of RCC in response to currently available VEGF/mTOR inhibitors are starting to 
emerge. Also, the rising costs of therapy associated with these novel drugs are another 
barrier to effective treatment. These highlight the need for more effective therapeutic agents 
for metastatic RCC. One approach would be simultaneous targeting of multiple molecular 
pathways. Pertinent to the molecular mechanism of VHL-HIF, there are at least 60 HIF-
regulated molecules that are engaged in tumor development and progression. This means 
that targeting the VEGF/mTOR pathway could be potentially abrogated by the opposing 
actions of numerous molecules favoring tumor progression. Therefore, given the 
heterogeneity of RCC, individualized, targeted treatment based on a preceding ‘molecular 
map’ of each tumor might represent an innovative therapeutic approach to achieving 
improved clinical outcomes. With the rapid advancements in technology, especially 
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microarrays and bioinformatics, the availability of clinically feasible platforms to generate 
molecular maps of individual tumors and customized treatment strategies may become a 
reality in the near future. 
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